Lerkanydypyn | Zanidip-Recordati tablets coated. 20 mg 56 pcs.
Special Price
$28.13
Regular Price
$37.00
In stock
SKU
BID491796
Latin name
ZANIDIP-RECORDATI
ZANIDIP-RECORDATI
Latin name
ZANIDIP-RECORDATI
Packing
56 pieces
ФармакологичРскоРдРйствимbr>
Занидип-РРкордати - блокатор «мРдлРнн х» кальциРв х каналов. ЛРрканидипин являРтся рацРмичРской смРсью право- (R) и лРвовращающихся (S) стРрРоизомРров, производноР1,4-дигидропиридина, способРн избиратРльно блокировать ток ионов кальция внутрь клРток сосудистой стРнки,сРрдРчн РклРтки и клРтки гладкой мускулатур . МРханизм гипотРнзивного дРйствия обусловлРн прям м рРлаксирующим дРйствиРм на гладком шРчн РклРтки сосудов. ОбладаРт пролонгированн м антигипРртРнзивн м дРйствиРм. ТРрапРвтичРский эффРкт достигаРтся чРрРз 5-7 часов послРприРма внутрь и длитРльность Рго сохраняРтся в тРчРниРсуток (24 часов). Благодаря в сокой сРлРктивности к гладком шРчн м клРткам сосудов отрицатРльноРинотропноРдРйствиРотсутствуРт. ЛРрканидипин являРтся мРтаболичРски нРйтральн м прРпаратом и нРоказ ваРт сущРствРнного воздРйствия на содРржаниРлипопротРинов и аполипопротРинов в с вороткРкрови, а такжРнРизмРняРт липидн й профиль у пациРнтов с артРриальной гипРртРнзиРй.
Indications
Essential mild to moderate hypertension.
Contraindications
Hypersensitivity,
decompensated heart failure, unstable angina, aortic stenosis, recent myocardial infarction (within 1 month),
severe impaired liver function, impaired renal function (CK less than 12 ml / min, s, children) not using reliable contraception, pregnancy, lactation,
childhood and adolescence (up to 18 years).
For LF containing lactose (optional): lactose intolerance, galactosemia, glucose / galactose malabsorption syndrome.
Caution. Renal and / or liver failure, CVD (without pacemaker), coronary heart disease, LV dysfunction, advanced age.
Special instructions
During treatment, care must be taken when driving vehicles and engaging in potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.
Composition
One film-coated tablet contains:
active ingredient: lercanidipine hydrochloride 20 mg
excipients: lactose monohydrate - 60 mg, microcrystalline cellulose - 78 mg, sodium carboxymethyl starch - 31 mg, povidone K30 - 9 mg, magnesium stearate - 2 mg.
sheath composition: opadray pink (02F25077) - 6 mg (hypromellose, talc, titanium dioxide (E171), macrogol 6000, red dye iron oxide (E172)).
Dosage and administration of
Zanidip-Recordati taken orally, in the morning, at least 15 minutes before meals, without chewing, washed down with a sufficient amount of water, 10 mg once a day.
Dose may be increased to 20 mg (depending on individual effect). Increasing the dose to 20 mg is carried out 2 weeks after the start of the drug.
In case of mild or moderate renal or hepatic insufficiency, increase the dose to 20 mg per day with caution.
Side effects
From the nervous system: rarely - drowsiness infrequently - headache, dizziness
from the immune system: very rarely - increased sensitivity
from the cardiovascular system: not often - tachycardia, palpitations "flushing" of blood to the skin of the face rarely - angina very rarely - fainting, pronounced decrease in blood pressure, chest pain, myocardial infarction
From the digestive system: rarely - nausea, vomiting, diarrhea, abdominal pain, dyspepsia, very rarely - increased activity of "liver" enzymes (reversible)
From skin: rarely - skin rash
From the musculoskeletal system: rarely - myalgia
From the urinary system: rarely - polyuria
General disorders and local reactions: not often - peripheral edema, rarely - asthenia, fatigue is very rare - gingival hyperplasia.
overdose
Symptoms: peripheral vasodilation with marked decrease in BP and reflex tachycardia, increase in frequency and duration of angina attacks, myocardial infarction.
Treatment: symptomatic therapy.
Storage Conditions
At a temperature not exceeding 30 РC. Keep out of reach of children.
PMA pills
Recordati chemical kai and the pharmaceutical industry, Italy
ZANIDIP-RECORDATI
Packing
56 pieces
ФармакологичРскоРдРйствимbr>
Занидип-РРкордати - блокатор «мРдлРнн х» кальциРв х каналов. ЛРрканидипин являРтся рацРмичРской смРсью право- (R) и лРвовращающихся (S) стРрРоизомРров, производноР1,4-дигидропиридина, способРн избиратРльно блокировать ток ионов кальция внутрь клРток сосудистой стРнки,сРрдРчн РклРтки и клРтки гладкой мускулатур . МРханизм гипотРнзивного дРйствия обусловлРн прям м рРлаксирующим дРйствиРм на гладком шРчн РклРтки сосудов. ОбладаРт пролонгированн м антигипРртРнзивн м дРйствиРм. ТРрапРвтичРский эффРкт достигаРтся чРрРз 5-7 часов послРприРма внутрь и длитРльность Рго сохраняРтся в тРчРниРсуток (24 часов). Благодаря в сокой сРлРктивности к гладком шРчн м клРткам сосудов отрицатРльноРинотропноРдРйствиРотсутствуРт. ЛРрканидипин являРтся мРтаболичРски нРйтральн м прРпаратом и нРоказ ваРт сущРствРнного воздРйствия на содРржаниРлипопротРинов и аполипопротРинов в с вороткРкрови, а такжРнРизмРняРт липидн й профиль у пациРнтов с артРриальной гипРртРнзиРй.
Indications
Essential mild to moderate hypertension.
Contraindications
Hypersensitivity,
decompensated heart failure, unstable angina, aortic stenosis, recent myocardial infarction (within 1 month),
severe impaired liver function, impaired renal function (CK less than 12 ml / min, s, children) not using reliable contraception, pregnancy, lactation,
childhood and adolescence (up to 18 years).
For LF containing lactose (optional): lactose intolerance, galactosemia, glucose / galactose malabsorption syndrome.
Caution. Renal and / or liver failure, CVD (without pacemaker), coronary heart disease, LV dysfunction, advanced age.
Special instructions
During treatment, care must be taken when driving vehicles and engaging in potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.
Composition
One film-coated tablet contains:
active ingredient: lercanidipine hydrochloride 20 mg
excipients: lactose monohydrate - 60 mg, microcrystalline cellulose - 78 mg, sodium carboxymethyl starch - 31 mg, povidone K30 - 9 mg, magnesium stearate - 2 mg.
sheath composition: opadray pink (02F25077) - 6 mg (hypromellose, talc, titanium dioxide (E171), macrogol 6000, red dye iron oxide (E172)).
Dosage and administration of
Zanidip-Recordati taken orally, in the morning, at least 15 minutes before meals, without chewing, washed down with a sufficient amount of water, 10 mg once a day.
Dose may be increased to 20 mg (depending on individual effect). Increasing the dose to 20 mg is carried out 2 weeks after the start of the drug.
In case of mild or moderate renal or hepatic insufficiency, increase the dose to 20 mg per day with caution.
Side effects
From the nervous system: rarely - drowsiness infrequently - headache, dizziness
from the immune system: very rarely - increased sensitivity
from the cardiovascular system: not often - tachycardia, palpitations "flushing" of blood to the skin of the face rarely - angina very rarely - fainting, pronounced decrease in blood pressure, chest pain, myocardial infarction
From the digestive system: rarely - nausea, vomiting, diarrhea, abdominal pain, dyspepsia, very rarely - increased activity of "liver" enzymes (reversible)
From skin: rarely - skin rash
From the musculoskeletal system: rarely - myalgia
From the urinary system: rarely - polyuria
General disorders and local reactions: not often - peripheral edema, rarely - asthenia, fatigue is very rare - gingival hyperplasia.
overdose
Symptoms: peripheral vasodilation with marked decrease in BP and reflex tachycardia, increase in frequency and duration of angina attacks, myocardial infarction.
Treatment: symptomatic therapy.
Storage Conditions
At a temperature not exceeding 30 РC. Keep out of reach of children.
PMA pills
Recordati chemical kai and the pharmaceutical industry, Italy
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review